fatty acid oxidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
By May 1619, the San Juan Bautista was in the Port of Luanda loading 350 African slaves for transport. The captain, a relative of de Acuña, sailed the Africans to Jamaica, during which time over one hundred of them died of illness. He traded twenty-four of them and set sail for Veracruz, but was attacked by two English ships, the White Lion and Treasurer. The captain surrendered, and the English ships split sixty of the Africans between them. The incident was described as follows:
=== Pharmacokinetics === After being taken by mouth, paracetamol is rapidly absorbed from the small intestine, while absorption from the stomach is negligible. Thus, the rate of absorption depends on stomach emptying. Food slows the stomach's emptying and absorption, but the total amount absorbed stays the same. In the same subjects, the time to reach peak plasma concentration of paracetamol was 20 minutes in a fasting state, compared to 90 minutes in a fed state. Furthermore, a high-carbohydrate meal reduced the peak plasma concentration by approximately fourfold, an effect not observed with high-protein or high-fat meals. Paracetamol's bioavailability is dose-dependent: it increases from 63% for 500 mg dose to 89% for 1000 mg dose. Its plasma terminal elimination half-life is 1.9–2.5 hours, and volume of distribution is roughly 50 L. Protein binding is negligible, except under the conditions of overdose, when it may reach 15–21%. The concentration in serum after a typical dose of paracetamol usually peaks below 30 μg/mL (200 μmol/L). After 4 hours, the concentration is usually less than 10 μg/mL (66 μmol/L).
During 1977, Czernilofsky published research that used affinity labeling to identify tRNA-binding sites on rat liver ribosomes. Several proteins, including L32/33, L36, L21, L23, L28/29 and L13 were implicated as being at or near the peptidyl transferase center.
Sources: en.wikipedia.org
Goodman impelled technical and procedural progress and popularized the open rhinoplasty approach. In 1987, Gunter reported the technical effectiveness of the open rhinoplasty approach for performing a secondary rhinoplasty; his improved techniques advanced the management of a failed nose surgery. In early 2021, it was reported that a trend that involved getting a rhinoplasty had emerged on the social media platform TikTok. The trend became known as the #NoseJobCheck trend and involved users of the platform posting videos that showed how their noses looked before and after their rhinoplasty surgeries, with a specific audio soundtracking the video. From October 2020 to January 2021, the #NoseJobCheck audio had been used in over 120,000 videos and videos with the #NoseJobCheck hashtag had accumulated over one billion views.
=== Founding and early years === On June 20, 1919, Roy W. Allen opened his first root beer stand in Lodi, California. The first day was for a homecoming celebration of soldiers who returned from battle in World War I. The following day, his stand was open for regular customers, selling root beer glasses for 5 cents (equivalent to $0.93 in 2025). The following year, Allen opened a second stand in Stockton, California. Shortly afterward, the effect of the period of prohibition that existed in the United States from 1920 to 1933 gave Allen and his stand with a beverage with "beer" in the name a heavy rebound. Four years later, A&W began when Allen and Frank Wright opened their drive-in restaurant in Sacramento, California, combining both of their initials for the name, and selling the root beer from Allen's stand. Curbside service was provided by tray boys and tray girls. In 1924, Allen purchased Frank Wright's stake in the business. In 1925, Allen began franchising the root beer, while the franchisee added the other menu items and operated at their discretion. Most of the restaurants that opened under this scheme were on the highways of the Central Valley region, mainly for travelers. This may have arguably been the first successful food-franchising operation. Allen sold the company in 1950 and retired. A lot of World War I veterans eventually founded A&W franchises throughout the US, while some of their descendants still own franchises. A&W's initial menu relied heavily on root beer and snacks, such as popcorn and peanuts, as well as sandwiches on sliced bread. In 1927, J.
=== Wet media milling (nanocrystal technology) === In wet media milling, the drug substance is suspended in an aqueous solution containing a stabilizing surfactant or polymer and circulated through a chamber filled with small (typically 0.2–0.5 mm) ceramic, glass, or polymer-coated beads. Bead-on-bead and bead-on-particle impacts progressively reduce the drug particle size to the 100–400 nm range, while the stabilizer adsorbs onto newly created surfaces and prevents agglomeration. The technology, commercialized as NanoCrystal by Elan Drug Technologies (later Alkermes), underpins several U.S. Food and Drug Administration–approved products, including sirolimus (Rapamune oral tablet, approved 2000), aprepitant (Emend, 2003), fenofibrate (Tricor 145 mg, 2004; Triglide, 2005), and megestrol acetate (Megace ES, 2005).
==== Education ==== Family, friends, and co-workers of a person with diabetes may provide life-saving treatment in the case of a hypoglycemic episode. It is important for these people to receive training on how to recognize hypoglycemia, what foods to help the hypoglycemic eat, how to administer injectable or intra-nasal glucagon, and how to use a glucose meter.
Sources: en.wikipedia.org
=== Awards === In 2007, British investors evaluated six nominated private companies and chose to Camurus as the best privately owned biotechnology company in the Medicon Valley. The company was awarded the Strictly Financing Award 2007. In 2013, Camurus was awarded CPhI Pharma Award for Best Innovation in Formulation.
The interpretation of the law of definite proportions in terms of the atomic theory of matter implied that the masses of atoms of various elements had definite ratios that depended on the elements. While the actual masses were unknown, the relative masses could be deduced from that law. In 1803 John Dalton proposed to use the (still unknown) atomic mass of the lightest atom, hydrogen, as the natural unit of atomic mass. This was the basis of the atomic weight scale. For technical reasons, in 1898, chemist Wilhelm Ostwald and others proposed to redefine the unit of atomic mass as 1/16 the mass of an oxygen atom. That proposal was formally adopted by the International Committee on Atomic Weights (ICAW) in 1903. That was approximately the mass of one hydrogen atom, but oxygen was more amenable to experimental determination. This suggestion was made before the discovery of isotopes in 1912. Physicist Jean Perrin had adopted the same definition in 1909 during his experiments to determine the atomic masses and the Avogadro constant. This definition remained unchanged until 1961. Perrin also defined the "mole" as an amount of a compound that contained as many molecules as 32 grams of oxygen (O2). He called that number the Avogadro number in honor of physicist Amedeo Avogadro.
=== Pharmacodynamics === Flmodafinil is a selective dopamine reuptake inhibitor (DRI). Its affinity (Ki) for the DAT is 4,090 nM. At the serotonin transporter (SERT), its affinity (Ki) was 48,700 nM (12-fold lower than for the DAT), and it had negligible affinity for the sigma σ1 receptor (Ki > 100,000 nM). The drug has been found to block the dopamine transporter (DAT) by 83%, to a greater extent than methylphenidate without unfavorable concomitant adrenergic effects. The drug is an atypical DRI similarly to modafinil. The affinities for the DAT of flmodafinil's enantiomers and modafinil have also been studied. The affinities (Ki) were 5,480 nM for armodafinil ((R)-modafinil), 2,970 nM for (S)-(+)-flmodafinil (JBG1-048), and 4,830 nM for (R)-(–)-flmodafinil (JBG1-049). Their affinities for the SERT and σ1 receptor have also been reported. Similarly to modafinil, (S)-(+)-flmodafinil and (R)-(–)-flmodafinil increase dopamine levels in the nucleus accumbens in animals. They have been found to increase dopamine levels by up to 150 to 200% of baseline at the highest assessed dose. These increases are much smaller than those elicited by amphetamine or cocaine. In a study comparing the wake-promoting effects of flmodafinil and modafinil, flmodafinil was found to maintain wakefulness over a significantly longer timeframe than modafinil. While the administration of neither compound resulted in sleep rebound, flmodafinil perturbed sleep architecture to a lesser degree than modafinil.
=== Neutrinos === The study of beta decay provided the first physical evidence for the existence of the neutrino. In both alpha and gamma decay, the resulting alpha or gamma particle has a narrow energy distribution, since the particle carries the energy from the difference between the initial and final nuclear states. However, the kinetic energy distribution, or spectrum, of beta particles measured by Lise Meitner and Otto Hahn in 1911 and by Jean Danysz in 1913 showed multiple lines on a diffuse background. These measurements offered the first hint that beta particles have a continuous spectrum. In 1914, James Chadwick used a magnetic spectrometer with one of Hans Geiger's new counters to make more accurate measurements which showed that the spectrum was continuous. The results, which appeared to be in contradiction to the law of conservation of energy, were validated by means of calorimetric measurements in 1929 by Lise Meitner and Wilhelm Orthmann. If beta decay were simply electron emission as assumed at the time, then the energy of the emitted electron should have a particular, well-defined value. For beta decay, however, the observed electrons had a broad distribution of energies. A second problem is related to the conservation of angular momentum. Molecular band spectra showed that the nuclear spin of nitrogen-14 is 1 (i.e., equal to the reduced Planck constant) and more generally that the spin is integral for nuclei of even mass number and half-integral for nuclei of odd mass number. This was later explained by the proton-neutron model of the nucleus.
Vasodilation and increased permeability of capillaries are a result of both H1 and H2 receptor types. Stimulation of histamine activates a histamine (H2)-sensitive adenylate cyclase of oxyntic cells, and there is a rapid increase in cellular [cAMP] that is involved in activation of H+ transport and other associated changes of oxyntic cells. Antihistamine drugs act by blocking histamine action at nerve endings. Cromoglicate-based drugs (sodium cromoglicate, nedocromil) block a calcium channel essential for mast cell degranulation, stabilizing the cell and preventing release of histamine and related mediators. Leukotriene antagonists (such as montelukast and zafirlukast) block the action of leukotriene mediators.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.